Author Affiliations1Novosibirsk State Medical University of Miszdrav of Russia 630091, Novosibirsk, Krasny av., 52
2Institute of Internal Medicine SB RAMS 630089, Novosibirsk, Boris Bogatkov str., 175/12
3Institute of Internal Medicine SB RAMS 630089, Novosibirsk, Boris Bogatkov str., 175/12
4Novosibirsk State Medical University Minzdrava Russia 630009, Novosibirsk, Krasnyi av., 52
5Novosibirsk State Medical University Minzdrava Russia 630009, Novosibirsk, Krasnyi av., 52
1. Berezina O.V., Vayner A.S., Voropayeva Ye.N. et al. // Sibirskoye meditsinskoye obozreniye. 2011. (3). 22–26. (in Russian)
2. Voropayeva Ye.N., Skvortsova N.V., Voyevoda M.I., Tarnovskiy R.V. // Byulleten' Sibirskogo Otdeleniya Rossiyskoy Akademii Meditsinskikh Nauk. 2011. (2). 26–30. (in Russian)
3. Pospelova T.I., Voropayeva Ye.N., Voyevoda M.I., Berezina O.V. // Gematologiya i transfuziologiya 2010. 55. (1). 11–17. (in Russian)
4. Cerhan J.R. Host genetics in follicular lymphoma // Best Pract. Res. Clin. Haematol. 2011. 24. (2). 121–134.
5. Havranek O., Spacek M., Hubacek P. et al. No association between the TP53 codon 72 polymorphism and risk or prognosis of Hodgkin and non-Hodgkin lymphoma // Leuk. Res. 2011. 35. (8). 1117–1119.
6. Hsieh L.L., Huang T.H., Chen I.H. et al. p53 polymorphisms associated with mutations in and loss of heterozygosity of the p53 gene in male oral squamous cell carcinomas in Taiwan // Br. J. Cancer. 2005. 92. (1). 30–35.
7. Kim H.N., Yu L., Kim N.Y. et al. Association with TP53 codon 72 polymorphism and the risk of non-Hodgkin lymphoma // Am. J. Hematol. 2010. 85. (10). 822–824.
8. Kochethu G., Delgado J., Pepper C. et al. Two germ line polymorphisms of the tumour suppressor gene p53 may influence the biology of chronic lymphocytic leukaemia // Leuk. Res. 2006. 30. (9). 1113–1118.
9. Lahiri O., Harris S., Packham G., Howell M. p53 pathway gene single nucleotide polymorphisms and chronic lymphocytic leukemia // Cancer Genet. Cytogenet. 2007. 179. (1). 36–44.
10. Majid A., Richards T., Dusanjh P. et al. TP53 codon 72 polymorphism in patients with chronic lymphocytic leukaemia: identification of a subgroup with mutated IGHV genes and poor clinical outcome // Br. J. Haematol. 2011. 153. 529–540.
11. Mitra S., Misra С., Singh R.K. et al. Association of specific genotype and haplotype of p53 gene with cervical cancer in India // J. Clin. Pathol. 2005. 58. 26–31.
12. Sturm I., Bosanquet A.G., Hummel M. et al. TP53 codonon 72 polymorphic variants of p53 are not related to drug resistance and disease prognosis // BMC Cancer. 2005. 5. 105.
13. Tada M., Furuuchi K., Kaneda M. et al. Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants // Cancerogenesis. 2001. 22. (3). 515–517.
14. Weiner A.S., Beresina O.V., Voronina E.N. et al. Polymorphisms in folate-metadolizing genes and risk of non-Hodgkin’s lymphoma // Leuk. Res. 2011. 35. 508–515.
15. Wrench D., Waters R., Carlotti E. et al. Clinical relevance of MDM2 SNP 309 and TP53 Arg72Pro in follicular lymphoma // Haematol. 2009. 94. (1). 148–150.
About Authors (Correspondence):
Voropaeva E.N. – candidate of medical sciences, researcher of laboratory for molecular genetic researches of therapeutic diseases
Berezina O.V. – assistant of the chair for therapy, hematology and blood transfusiology, e-mail: ovberezina@mail.ru
Ovchinnikov V.S. – clinical resident of the chair for therapy, hematology and blood transfusiology, post_gem@mail.ru
Voevoda M.I. – corresponding member of RAMS, director
Pospelova T.I. – doctor of medical sciences, professor, head of the chair for therapy, hematology and transfusiology, e-mail: post_gem@mail.ru